Growth-promoting effect of a protein-free hemodialysate used in situations of hypoxia and for tissue repair as measured via stimulation of S6-kinase.
Solcoseryl is the low-molecular weight fraction of calf blood as manufactured by counterflow dialysis. This hemodialysate (HD) is in clinical use in situations involving hypoxia and for the normalization of tissue repair. The influence of the HD on ZR-75 cells was tested. These cells preferably express receptors for Epidermal Growth Factor (EGF)/Transforming Growth Factor alpha (TGF-alpha) or Somatomedin C (SMC = insulin like growth factor I resp. ILA-I) and react upon stimulation by enhancement of their S6-kinase activity, the latter being a prerequisite for growth. The functional presence of one or several of these peptide growth factors should therefore reflect in a stimulation of S6-kinase activity.
Fabbro
D
D
Department of Research, University of Basel Medical School, Switzerland.
Imber
R
R
Huggel
K
K
Baschong
W
W
D000183:Actihaemyl / Q000627:therapeutic use*; D000368:Aged; D015687:Cell Hypoxia / Q000187:drug effects*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D019893:Ribosomal Protein S6 Kinases; D016211:Transforming Growth Factor alpha / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D007328:Insulin; D016211:Transforming Growth Factor alpha; D000183:Actihaemyl; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D017346:Protein Serine-Threonine Kinases; D019893:Ribosomal Protein S6 Kinases